Guangzhou Medprin Biomedical Technology Co., Ltd.
Announcement on the Vesting Results and Share Listing of the Reserved Portion of the 2023 Restricted Stock Incentive Plan for the Second Vesting Period
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Key Information Prompt:
-
The listing and circulation date of the restricted shares for this vesting is August 3, 2026. The second tranche of restricted shares in this vesting has no lock-up period.
-
The number of restricted shares to be vested in this batch is 33,089 shares, accounting for 0.05% of the Company's total share capital (excluding repurchased shares, the same below).
-
The number of recipients for this vesting is 2.
-
The source of shares for this incentive plan is the ordinary RMB A shares issued by the Company to the incentive recipients.
Guangzhou Medprin Biomedical Technology Co., Ltd. (hereinafter referred to as the "Company") held the 24th meeting of the third Board of Directors on July 14, 2026, and reviewed and approved the "Proposal on the Achievement of Vesting Conditions for the Second Vesting Period of the Reserved Portion of the 2023 Restricted Stock Incentive Plan." The Board of Directors believes that the vesting conditions for the second vesting period of the reserved portion of the Company's 2023 Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan," "this Incentive Plan," or "the current Incentive Plan") have been met, and agreed to handle the relevant vesting matters for 2 eligible incentive recipients. The total number of restricted shares that can be vested in this batch is 33,089 shares.
Recently, the Company completed the share registration work for the second vesting period of the reserved portion of the incentive plan. The relevant matters are hereby explained as follows:
I. Summary of the Implementation of the Incentive Plan
(I) Main Content of the Incentive Plan
On August 17, 2023, the Company convened the first extraordinary general meeting of shareholders in 2023 and approved the "Proposal on the <Guangzhou Medprin Biomedical Technology Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)> and its Summary," among other proposals. The main contents of the "Incentive Plan" are as follows:
-
Incentive Type: Second Class Restricted Shares
-
Source of Shares for the Incentive Plan
The underlying shares involved in the incentive plan are ordinary RMB A shares issued by the Company to the incentive recipients.
- Number of Restricted Shares Granted
The number of restricted shares granted to incentive recipients under the incentive plan is 1.868 million shares, accounting for approximately 2.83% of the Company's total share capital as of the disclosure date of the incentive plan draft, which was 66.062951 million shares. Among them, 1.768 million shares were granted for the first time, accounting for approximately 2.68% of the Company's total share capital as of the disclosure date of the incentive plan draft, which was 66.062951 million shares, or 94.65% of the total restricted shares granted under the incentive plan. 0.1 million shares were granted as reserved shares, accounting for approximately 0.15% of the Company's total share capital as of the disclosure date of the incentive plan draft, which was 66.062951 million shares.
The total number of restricted shares granted under the incentive plan accounts for 5.35% of the total number of restricted shares granted.
- Scope of Incentive Recipients
The first grant of the incentive plan covered a total of 49 incentive recipients, including directors, senior management personnel, middle management personnel, and key technical and business backbones employed by the Company (including its subsidiaries) at the time of the Company's announcement of the incentive plan. This does not include independent directors, supervisors, or foreign employees of Medprin.